First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Primary objective: to evaluate whether the addition of sunitinib prolongates the
Progression-Free Survival (PFS) in patients with advanced pancreatic cancer receiving
first-line gemcitabine chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Central European Society for Anticancer Drug Research